Delivery and Safety of Inhaled Interferon-γ in Idiopathic Pulmonary Fibrosis
Publication: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Volume 25, Issue Number 2
Abstract
Background: Inhaled interferon-γ aerosol (aINF-γ) may be effective treatment for idiopathic pulmonary fibrosis (IPF). We evaluated safety and delivery of aIFN-γ (100 μg 3 times/week) in 10 IPF patients using the I-neb (Philips Respironics, Parsippany, NJ).
Methods: IFN-γ activity in the aerosol was confirmed by viral inhibition. Ten patients with an average age of 68 diagnosed with IPF (American Thoracic Society/European Respiratory Society consensus guidelines) were enrolled. In vivo deposition was measured via a gamma camera. The nebulizer recorded patient adherence to therapy. Pulmonary function tests [PFTs, forced vital capacity (FVC), total lung capacity (TLC), diffusing capacity for carbon monoxide (DLCO)] and the 6-min walk test were measured at baseline, and every 12–14 weeks for 80 weeks. Bronchoalveolar lavage (BAL) of the middle lobe was performed at baseline and 28 weeks. BAL and plasma samples were analyzed for chemokines and cytokines, including INF-γ.
Results: All 10 patients tolerated 80 weeks of inhaled IFN-γ well, with no systemic side effects. True adherence with aerosol treatment averaged 96.7±4.81% (±SEM). In vivo lung deposition averaged 65.4±4.8μg and oropharyngeal deposition 12.6±3.0 μg. BAL IFN-γ increased 60-fold and profibrotic cytokines (FGP-2, Flt-3 ligand, IL-5) were significantly decreased; IFN-γ plasma levels were unchanged. PFTs showed minimal change in FVC. Post hoc analysis indicated that the slope of decline in TLC and DLCO reversed after beginning therapy. The 6-min walk was unchanged.
Conclusions: IFN-γ is safe in IPF and can be effectively delivered to lung parenchyma. PFTs remained stable throughout the trial. Reversal of pretherapy PFT decline may define an end-point for future clinical trials.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Schwartz DAHelmers RAGalvin JRVan Fossen DSFrees KLDayton CSBurmeister LFHunninghake GW. Determinants of survival in idiopathic pulmonary fibrosisAm J Respir Crit Care Med1994149450-454. 1. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, and Hunninghake GW: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994;149:450–454.
2.
Douglas WWRyu JHSchroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survivalAm J Respir Crit Care Med20001611172-1178. 2. Douglas WW, Ryu JH, and Schroeder DR: Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med. 2000;161:1172–1178.
3.
Bjoraker JARyu JHEdwin MKMyers JLTazelaar HDSchroeder DROfford KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosisAm J Respir Crit Care Med1998157199-203. 3. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, and Offord KP: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199–203.
4.
Azuma ANukiwa TTsuboi ESuga MAbe SNakata KTaguchi YNagai SItoh HOhi MSato AKudoh S. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosisAm J Respir Crit Care Med20051711040-1047. 4. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, and Kudoh S: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047.
5.
Demedts MBehr JBuhl RCostabel UDekhuijzen RJansen HMMacNee WThomeer MWallaert BLaurent FNicholson AGVerbeken EKVerschakelen JFlower CDCapron FPetruzzelli SDe Vuyst Pvan den Bosch JMRodriguez-Becerra ECorvasce GLankhorst ISardina MMontanari M. High-dose acetylcysteine in idiopathic pulmonary fibrosisN Engl J Med20053532229-2242. 5. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, and Montanari M: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229–2242.
6.
Raghu GBrown KKBradford WZStarko KNoble PWSchwartz DAKing TE Jr. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosisN Engl J Med2004350125-133. 6. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, and King TE Jr: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–133.
7.
Raghu GBrown KKCostabel UCottin Vdu Bois RMLasky JAThomeer MUtz JPKhandker RKMcDermott LFatenejad S. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trialAm J Respir Crit Care Med2008178948-955. 7. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, and Fatenejad S: Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178:948–955.
8.
Strieter RMMehrad B. New mechanisms of pulmonary fibrosisChest20091361364-1370. 8. Strieter RM and Mehrad B: New mechanisms of pulmonary fibrosis. Chest. 2009;136:1364–1370.
9.
King TE Jr.Pardo ASelman M. Idiopathic pulmonary fibrosisLancet2011. 9. King TE Jr., Pardo A, and Selman M: Idiopathic pulmonary fibrosis. Lancet. 2011.
10.
Wynn TA. Integrating mechanisms of pulmonary fibrosisJ Exp Med20112081339-1350. 10. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208:1339–1350.
11.
Strieter RM. What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosisProc Am Thorac Soc20085305-310. 11. Strieter RM: What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc. 2008;5:305–310.
12.
Homer RJElias JALee CGHerzog E. Modern concepts on the role of inflammation in pulmonary fibrosisArch Pathol Lab Med2011135780-788. 12. Homer RJ, Elias JA, Lee CG, and Herzog E: Modern concepts on the role of inflammation in pulmonary fibrosis. Arch Pathol Lab Med. 2011;135:780–788.
13.
King TE JrAlbera CBradford WZCostabel UHormel PLancaster LNoble PWSahn SASzwarcberg JThomeer MValeyre Ddu Bois RM. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialLancet2009374222-228. 13. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, and du Bois RM: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374:222–228.
14.
Strieter RMStarko KMEnelow RINoth IValentine VG. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosisAm J Respir Crit Care Med2004170133-140. 14. Strieter RM, Starko KM, Enelow RI, Noth I, and Valentine VG: Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2004;170:133–140.
15.
Jaffe HABuhl RMastrangeli AHolroyd KJSaltini CCzerski DJaffe HSKramer SSherwin SCrystal RG. Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lungJ Clin Invest199188297-302. 15. Jaffe HA, Buhl R, Mastrangeli A, Holroyd KJ, Saltini C, Czerski D, Jaffe HS, Kramer S, Sherwin S, and Crystal RG: Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. J Clin Invest. 1991;88:297–302.
16.
Condos RHull FPSchluger NWRom WNSmaldone GC. Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosisChest20041252146-2155. 16. Condos R, Hull FP, Schluger NW, Rom WN, and Smaldone GC: Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis. Chest. 2004;125:2146–2155.
17.
Raju BHoshino YKuwabara KBelitskaya IPrabhakar SCanova AGold JACondos RPine RIBrown SRom WNWeiden MD. Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosisInfect Immun2004721275-1283. 17. Raju B, Hoshino Y, Kuwabara K, Belitskaya I, Prabhakar S, Canova A, Gold JA, Condos R, Pine RI, Brown S, Rom WN, and Weiden MD: Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect Immun. 2004;72:1275–1283.
18.
Dawson RCondos RTse DHuie MLRess STseng CHBrauns CWeiden MHoshino YBateman ERom WN. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosisPLoS One20094e6984. 18. Dawson R, Condos R, Tse D, Huie ML, Ress S, Tseng CH, Brauns C, Weiden M, Hoshino Y, Bateman E, and Rom WN: Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One. 2009;4:e6984.
19.
Smaldone GC. Physiological and pathological considerations for aerosol deposition: expiration and models of depositionJ Aerosol Med200013387-391. 19. Smaldone GC: Physiological and pathological considerations for aerosol deposition: expiration and models of deposition. J Aerosol Med. 2000;13:387–391.
20.
Bennett WDSmaldone GC. Human variation in the peripheral air-space deposition of inhaled particlesJ Appl Physiol1987621603-1610. 20. Bennett WD and Smaldone GC: Human variation in the peripheral air-space deposition of inhaled particles. J Appl Physiol. 1987;62:1603–1610.
21.
Nikander KPrince ICoughlin SWarren STaylor G. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPAJ Aerosol Med Pulm Drug Deliv201023Suppl 1S37-S43. 21. Nikander K, Prince I, Coughlin S, Warren S, and Taylor G: Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S37–S43.
22.
Skaria SSmaldone GCOmron NE. U22: Comparison between vibrating mesh and jet nebulizerJ Aerosol Med Pulm Drug Deliv201023173-180. 22. Skaria S, Smaldone GC, Omron NE: U22: Comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv 2010;23:173–180.
23.
Nikander KArheden LDenyer JCobos N. Parents' adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) systemJ Aerosol Med200316273-281. 23. Nikander K, Arheden L, Denyer J, Cobos N: Parents' adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) system. J Aerosol Med 2003;16:273–281.
24.
Solomita MSmaldone GC. Reconciliation of cascade impaction during wet nebulizationJ Aerosol Med Pulm Drug Deliv20092211-18. 24. Solomita M and Smaldone GC: Reconciliation of cascade impaction during wet nebulization. J Aerosol Med Pulm Drug Deliv. 2009;22:11–18.
25.
O'Riordan TGGreco MJPerry RJSmaldone GC. Nebulizer function during mechanical ventilationAm Rev Respir Dis19921451117-1122. 25. O'Riordan TG, Greco MJ, Perry RJ, and Smaldone GC: Nebulizer function during mechanical ventilation. Am Rev Respir Dis. 1992;145:1117–1122.
26.
McPeck MTandon RHughes KSmaldone GC. Aerosol delivery during continuous nebulizationChest19971111200-1205. 26. McPeck M, Tandon R, Hughes K, and Smaldone GC: Aerosol delivery during continuous nebulization. Chest. 1997;111:1200–1205.
27.
American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatmentAm J Respir Crit Care Med2000161646-664. 27. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med. 2000;161:646–664.
28.
Bender RLange S. Adjusting for multiple testing—when and how?J Clin Epidemiol200154343-349. 28. Bender R and Lange S: Adjusting for multiple testing—when and how? J Clin Epidemiol. 2001;54:343–349.
29.
Spencer LTHumphries JEBrantly ML. Antibody response to aerosolized transgenic human alpha1-antitrypsinN Engl J Med20053522030-2031. 29. Spencer LT, Humphries JE, and Brantly ML: Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med. 2005;352:2030–2031.
30.
Porter S. Human immune response to recombinant human proteinsJ Pharm Sci2001901-11. 30. Porter S: Human immune response to recombinant human proteins. J Pharm Sci. 2001;90:1–11.
31.
Sangwan SCondos RSmaldone GC. Lung deposition and respirable mass during wet nebulizationJ Aerosol Med200316379-386. 31. Sangwan S, Condos R, and Smaldone GC: Lung deposition and respirable mass during wet nebulization. J Aerosol Med. 2003;16:379–386.
32.
Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigmNat Rev Immunol20044583-594. 32. Wynn TA: Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583–594.
33.
Hoffmann KFCheever AWWynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasisJ Immunol20001646406-6416. 33. Hoffmann KF, Cheever AW, and Wynn TA: IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol. 2000;164:6406–6416.
34.
Gharaee-Kermani MPhan SH. Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosisAm J Respir Cell Mol Biol199716438-447. 34. Gharaee-Kermani M and Phan SH: Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 1997;16:438–447.
35.
Gharaee-Kermani MMcGarry BLukacs NHuffnagle GEgan RWPhan SH. The role of IL-5 in bleomycin-induced pulmonary fibrosisJ Leukoc Biol199864657-666. 35. Gharaee-Kermani M, McGarry B, Lukacs N, Huffnagle G, Egan RW, and Phan SH: The role of IL-5 in bleomycin-induced pulmonary fibrosis. J Leukoc Biol. 1998;64:657–666.
36.
Hetzel MBachem MAnders DTrischler GFaehling M. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblastsLung2005183225-237. 36. Hetzel M, Bachem M, Anders D, Trischler G, and Faehling M: Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung. 2005;183:225–237.
37.
Khalil NXu YDO'Connor RDuronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNKJ Biol Chem200528043000-43009. 37. Khalil N, Xu YD, O'Connor R, and Duronio V: Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem. 2005;280:43000–43009.
38.
Wodnar-Filipowicz A. Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrowNews Physiol Sci200318247-251. 38. Wodnar-Filipowicz A: Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol Sci. 2003;18:247–251.
39.
Ley BCollard HRKing TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2011183431-440. 39. Ley B, Collard HR, and King TE Jr: Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440.
Information & Authors
Information
Published In
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Volume 25 • Issue Number 2 • April 2012
Pages: 79 - 87
PubMed: 22360317
Copyright
Copyright 2012, Mary Ann Liebert, Inc.
History
Published in print: April 2012
Published online: 30 March 2012
Published ahead of print: 23 February 2012
Accepted: 20 January 2012
Received: 9 September 2011
Topics
Authors
Author Disclosure Statement
Dr. Smaldone serves as a consultant to Philips Respironics. Stony Brook University and New York University jointly hold patents in the treatment of IPF with inhaled IFN-γ.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.